BTIG Research Reaffirms “Buy” Rating for Sensei Biotherapeutics (NASDAQ:FTH)

Sensei Biotherapeutics (NASDAQ:FTH)‘s stock had its “buy” rating restated by analysts at BTIG Research in a research report issued on Tuesday, Benzinga reports. They presently have a $55.00 target price on the stock. BTIG Research‘s price target would suggest a potential upside of 202.08% from the company’s previous close.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Monday, September 14th. Wall Street Zen lowered shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, September 26th. TD Cowen began coverage on shares of Sensei Biotherapeutics in a report on Wednesday, September 9th. They issued a “buy” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of Sensei Biotherapeutics in a report on Tuesday, August 11th. Finally, Citizens Jmp initiated coverage on shares of Sensei Biotherapeutics in a research report on Monday, July 20th. They issued an “outperform” rating and a $51.00 price target for the company. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $56.25.

Sensei Biotherapeutics Trading Up 8.2%

Shares of NASDAQ FTH traded up $1.38 during mid-day trading on Tuesday, reaching $18.21. The company had a trading volume of 90,177 shares, compared to its average volume of 248,033. The stock has a 50 day simple moving average of $29.91. Sensei Biotherapeutics has a 52-week low of $7.45 and a 52-week high of $42.14. The stock has a market cap of $470.47 million, a PE ratio of -0.13 and a beta of -0.29.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, beating analysts’ consensus estimates of ($5.04) by $2.20. Research analysts predict that Sensei Biotherapeutics will post -13.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC acquired a new position in shares of Sensei Biotherapeutics in the second quarter valued at approximately $307,000. Renaissance Technologies LLC lifted its holdings in shares of Sensei Biotherapeutics by 178.2% during the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after purchasing an additional 20,525 shares during the period. Bank of America Corp DE lifted its holdings in shares of Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after purchasing an additional 32,719 shares during the period. Stempoint Capital LP acquired a new stake in shares of Sensei Biotherapeutics during the first quarter worth $4,188,000. Finally, Alyeska Investment Group L.P. purchased a new position in Sensei Biotherapeutics in the 2nd quarter valued at $3,610,000. 10.50% of the stock is currently owned by hedge funds and other institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei’s pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company’s ImmunoPhage platform.